Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been given an average recommendation of “Moderate Buy” by the eleven research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $12.1250.

STTK has been the topic of several recent analyst reports. Wedbush raised their target price on shares of Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Weiss Ratings raised shares of Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Jefferies Financial Group upgraded shares of Shattuck Labs to an “outperform” rating and set a $7.00 price target on the stock in a research report on Friday, June 5th. Citigroup raised shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Friday, June 5th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Shattuck Labs in a research report on Friday, July 24th. They set an “overweight” rating and a $10.00 price objective for the company.

Insider Activity

In related news, insider Abhinav A. Shukla sold 23,365 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total transaction of $165,424.20. Following the completion of the sale, the insider directly owned 86,380 shares in the company, valued at $611,570.40. This represents a 21.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Clay B. Siegall acquired 62,500 shares of Shattuck Labs stock in a transaction that occurred on Tuesday, June 9th. The stock was acquired at an average cost of $4.00 per share, for a total transaction of $250,000.00. Following the completion of the purchase, the director directly owned 318,608 shares of the company’s stock, valued at $1,274,432. This represents a 24.40% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have sold 53,875 shares of company stock worth $379,305. Insiders own 8.79% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of STTK. OMERS ADMINISTRATION Corp grew its holdings in shares of Shattuck Labs by 25.7% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 33,300 shares of the company’s stock valued at $214,000 after purchasing an additional 6,800 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Shattuck Labs by 5.4% in the 1st quarter. The Manufacturers Life Insurance Company now owns 142,300 shares of the company’s stock valued at $915,000 after purchasing an additional 7,244 shares during the last quarter. Virtu Financial LLC acquired a new stake in Shattuck Labs in the third quarter valued at approximately $38,000. Squarepoint Ops LLC bought a new stake in shares of Shattuck Labs during the third quarter worth $46,000. Finally, State of Wyoming bought a new stake in shares of Shattuck Labs during the second quarter worth $151,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Stock Performance

NASDAQ:STTK opened at $7.49 on Thursday. The company has a market cap of $574.33 million, a price-to-earnings ratio of -14.69 and a beta of 1.08. Shattuck Labs has a fifty-two week low of $0.76 and a fifty-two week high of $8.33. The stock has a fifty day moving average price of $6.32 and a 200-day moving average price of $5.92.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). Research analysts predict that Shattuck Labs will post -0.5 EPS for the current fiscal year.

Key Headlines Impacting Shattuck Labs

Here are the key news stories impacting Shattuck Labs this week:

• Positive Sentiment: Positive Phase 1 data for SL-325: Shattuck reported a favorable safety profile, low immunogenicity, no evidence of DR3 agonism and durable blockade of TL1A binding. The results support the company’s view that SL-325 could potentially allow quarterly dosing and compete favorably in the inflammatory bowel disease market. Positive Phase 1 Data for SL-325
• Positive Sentiment: Phase 2b trial approaching: The RECEPTIVE-CD1 study of SL-325 in approximately 232 Crohn’s disease patients is expected to begin in the third quarter of 2026. The primary efficacy data are expected in the first half of 2028, creating a major future catalyst if the trial demonstrates clinical benefit. SL-325 Crohn’s Trial Update
• Positive Sentiment: Extended cash runway: Cash, cash equivalents and short-term investments totaled approximately $208.3 million at June 30, 2026, helped by an $86.2 million public offering and $57.1 million from exercised warrants. Management expects current resources to fund operations into 2029, reducing near-term financing risk.
• Positive Sentiment: Pipeline expansion: Shattuck introduced SL-846, a DR3 x IL-23 receptor bispecific antibody, with initial Phase 1 data expected in 2027. This adds another potential growth opportunity beyond SL-325.
• Neutral Sentiment: Earnings met expectations: Second-quarter EPS was a loss of $0.12, matching consensus. However, the company generated no revenue and remains dependent on clinical development and capital markets.
• Neutral Sentiment: Analyst outlook remains constructive: HC Wainwright lowered its price target from $18 to $14 but maintained a Buy rating. Analysts overall have issued a Moderate Buy consensus, with targets substantially above the current trading level. Consensus Analyst Rating
• Negative Sentiment: Higher operating losses: Second-quarter net loss increased to $15.2 million from $12.5 million a year earlier, while R&D spending rose to $11.7 million. The company’s valuation therefore continues to depend heavily on successful future trial results.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.